Adolor IND (correction)
This article was originally published in The Pink Sheet Daily
Potential convulsant activity is an issue for the Delta opioid receptor class, but FDA has not asked Adolor to examine the potential activity as part of its clinical hold on the IND of the firm's compound ADL5859. In a Jan. 30 1article, "The Pink Sheet" DAILY incorrectly reported that FDA had asked for information on that as part of the clinical hold
You may also be interested in...
Product is on clinical hold following FDA's request for additional preclinical safety studies.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.